dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
Published 6 years ago • 251 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
1:44
dr. oxnard on delaying second-line treatment in egfr-mutant lung cancer
-
1:31
dr. oxnard on detecting resistance mechanisms after treatment with osimertinib
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
5:45
osimertinib in t790m-mutant lung cancer
-
10:20
role of adjuvant osimertinib in early stage nsclc
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:45
geoffrey oxnard, md, on the flaura study impacting treatment selection in egfr mutant lung cancer
-
1:21
dr. kris on the fda approval of dacomitinib in egfr nsclc
-
7:00
flaura trial: impact of os data in advanced nsclc
-
4:49
tatton trial – savolitinib plus osimertinib in egfr-mutated, met-amplified nsclc | lecia sequist
-
1:11
dr. sequist on rationale for tatton trial in egfr-mutant lung cancer
-
5:52
treatment of egfr nsclc after osimertinib
-
6:06
osimertinib, the standard for egfr nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
1:52
dr. goldberg discusses osimertinib in nsclc
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc